Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 5/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGFR | P43088 | 4/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632380 | 0.83 | GABBR2 (0.42) | GABBR2GABBR1CYP3A4LMNACYP2C9 | |
| SCHEMBL21632393 | 0.82 | PTGFR (0.44) | GABBR2GABBR1CYP3A4LMNACYP2C9 | |
| SCHEMBL21632069 | 0.82 | PTGFR (0.43) | GABBR2GABBR1CYP3A4LMNACYP2C9 | |
| SCHEMBL21656324 | 0.80 | APP (0.33) | GABBR2GABBR1CYP3A4LMNACYP2C9 | |
| SCHEMBL21631986 | 0.79 | PTGFR (0.45) | GABBR2GABBR1CYP3A4LMNACYP2C9 | |
| SCHEMBL21632068 | 0.78 | GABBR2 (0.41) | GABBR2GABBR1CYP3A4LMNACYP2C9 | |
| SCHEMBL20534596 | 0.78 | FFAR4 (0.41) | CYP3A4CYP1A2PTGFRFFAR4FFAR1 | |
| SCHEMBL21956255 | 0.76 | GABBR2 (0.42) | GABBR2GABBR1CYP3A4LMNACYP2C9 | |
| SCHEMBL21632159 | 0.76 | PTGFR (0.39) | GABBR2GABBR1CYP3A4LMNACYP2C9 | |
| SCHEMBL21632035 | 0.75 | CCR1 (0.36) | CYP3A4CYP1A2CYP2D6CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-19 | — | — | US | disclosed |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | GABBR2 1861/4885GABBR1 1557/4885CYP3A4 514/4885 |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, ARG2, GOT2 | GABBR2 1700/4885GABBR1 1451/4885CYP3A4 747/4885 |
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | AADAC, ARG2, GOT2 | GABBR2 1700/4885GABBR1 1451/4885CYP3A4 747/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | GABBR2 1861/4885GABBR1 1557/4885CYP3A4 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.